Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNB4 | O00305 | 2/20 | 0.49 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.49 |
| ▸ | CACNG3 | O60359 | 2/20 | 0.49 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.49 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.49 |
| ▸ | CACNB3 | P54284 | 2/20 | 0.49 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.49 |
| ▸ | CACNG7 | P62955 | 2/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.49 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.49 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.49 |
| ▸ | CACNG1 | Q06432 | 2/20 | 0.49 |
| ▸ | CACNB2 | Q08289 | 2/20 | 0.49 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.49 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.49 |
| ▸ | CACNA1E | Q15878 | 2/20 | 0.49 |
| ▸ | CACNA2D4 | Q7Z3S7 | 2/20 | 0.49 |
| ▸ | CACNA2D3 | Q8IZS8 | 2/20 | 0.49 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30740730 | 0.85 | MRGPRX4 (0.46) | MRGPRX4 | |
| SCHEMBL29826215 | 0.83 | CYP2C9 (0.44) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL24793341 | 0.82 | MRGPRX4 (0.48) | MRGPRX4PDE4BFNTAFNTBCNR1 | |
| SCHEMBL27168908 | 0.82 | MRGPRX4 (0.48) | MRGPRX4PDE4BFNTAFNTBCNR1 | |
| SCHEMBL25113657 | 0.81 | CACNB4 (0.52) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL29826364 | 0.81 | CACNB4 (0.47) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL31058712 | 0.81 | GPR119 (0.52) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL29826284 | 0.81 | GPR119 (0.54) | GPR119 | |
| SCHEMBL27111205 | 0.81 | GPR119 (0.54) | GPR119 | |
| SCHEMBL16759524 | 0.81 | PDE4B (0.55) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | CARMOT THERAPEUTICS INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4563199-A2 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250154137-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| US-20240252492-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| EP-4284795-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230089073-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2023-03-23 | — | — | US | disclosed |
| WO-2022165076-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154137-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | CACNB4 1389/4885CACNA1A 1052/4885CACNA1G 715/4885 |
| US-20230089073-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | CACNB4 1389/4885CACNA1A 1052/4885CACNA1G 715/4885 |
| US-20240252492-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | CACNB4 1389/4885CACNA1A 1052/4885CACNA1G 715/4885 |
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | GLP1R, GCGR, GIPR | CACNB4 1389/4885CACNA1A 1052/4885CACNA1G 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.